Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
Volume 47, Issue 6, Pages 855-868
Publisher
Springer Science and Business Media LLC
Online
2022-09-30
DOI
10.1007/s13318-022-00793-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
- (2021) Daryl Hodge et al. CLINICAL PHARMACOKINETICS
- Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
- (2021) Jean-Michel Molina et al. Lancet HIV
- Microarray patches: Breaking down the barriers to contraceptive care and HIV prevention for women across the globe
- (2021) Alejandro J. Paredes et al. ADVANCED DRUG DELIVERY REVIEWS
- Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
- (2021) Kelly Bleasby et al. Viruses-Basel
- Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial
- (2021) Randolph P. Matthews et al. NATURE MEDICINE
- Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
- (2020) Dirk Schürmann et al. Lancet HIV
- Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research
- (2020) Denise A. Cobb et al. Expert Opinion on Drug Delivery
- Microneedle Array: Applications, Recent Advances, and Clinical Pertinence in Transdermal Drug Delivery
- (2020) Jitu Halder et al. Journal of Pharmaceutical Innovation
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Microneedle array systems for long-acting drug delivery
- (2020) Lalit K. Vora et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK
- (2019) Rajith K.R. Rajoli et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Extended Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention
- (2018) Stephanie E. Barrett et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
- (2018) Mohamad Shebley et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591
- (2018) Martin Markowitz et al. Current Opinion in HIV and AIDS
- The promise and pitfalls of long-acting injectable agents for HIV prevention
- (2016) Raphael J. Landovitz et al. Current Opinion in HIV and AIDS
- Oral Administration of the Nucleoside EFdA (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque
- (2015) Cheryl A. Stoddart et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers
- (2014) Wei Zhang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms
- (2014) Eleftherios Michailidis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- HIV infection: epidemiology, pathogenesis, treatment, and prevention
- (2014) Gary Maartens et al. LANCET
- Application of physiologically-based toxicokinetic modelling in oral-to-dermal extrapolation of threshold doses of cosmetic ingredients
- (2014) M. Gajewska et al. TOXICOLOGY LETTERS
- An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry
- (2012) Sieto Bosgra et al. CRITICAL REVIEWS IN TOXICOLOGY
- Setting Up a Standardized Peripheral Blood Mononuclear Cells Processing Laboratory to Support Multi-center HIV/AIDS Vaccine and Intervention Trials
- (2011) Harr Freeya Njai et al. Labmedicine
- Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis
- (2008) Sheila Annie Peters CLINICAL PHARMACOKINETICS
- Prediction of drug distribution within blood
- (2008) Paulo Paixão et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started